Biomea Fusion, Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- Biomea Fusion, Inc. price/book ratio for the quarter ending 2026-06-30 was 8.84, a 131.11% increase year-over-year.
- Biomea Fusion, Inc. price/book ratio for the quarter ending 2026-03-31 was 5.83, a 109.42% increase year-over-year.
- Biomea Fusion, Inc. price/book ratio for the quarter ending 2025-12-31 was 3.01, a 10.16% increase year-over-year.
- Biomea Fusion, Inc. price/book ratio for the quarter ending 2025-09-30 was 7.73, a 60.54% increase year-over-year.
- Biomea Fusion, Inc. price/book ratio for fiscal 2026 was 8.84.
- Biomea Fusion, Inc. price/book ratio for fiscal 2025 was 3.01, a 10.16% increase from fiscal 2024.
- Biomea Fusion, Inc. price/book ratio for fiscal 2024 was 2.73, a 11.23% decline from fiscal 2023.
- Biomea Fusion, Inc. price/book ratio for fiscal 2023 was 3.08, a 34.03% increase from fiscal 2022.
- Available history
- 2021-06-30 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |